HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Health Canada advisory

This article was originally published in The Tan Sheet

Executive Summary

Canadian health agency has issued a Customs Alert to the Canada Border Services Agency "to monitor importation" of ayurvedic herbal medicinal products found to contain high levels of heavy metals. The alert cites brands named in a recent Journal of the American Medical Association study by Robert Saper, MD, Harvard Medical School, et al., that found detectable levels of lead in 13 of 70 of such imported products (1"The Tan Sheet" Dec. 20, 2004, p. 13). "Further action will be taken if any of the remaining products are confirmed to be sold in Canada, and if laboratory testing determines that heavy metal levels exceed Canadian exposure limits," the document states...

You may also be interested in...



Heavy Metals In Imported Herbals Warrant Supplement Testing – JAMA Study

An FDA-mandated import alert would be a more appropriate response to imported dietary supplements containing trace levels of heavy metals than would required testing of such products, the American Herbal Products Association said in response to a study in the Dec. 15 Journal of the American Medical Association

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS126752

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel